


NEW DEVELOPMENTS IN MULTIPLE MYELOMA



FRIDAY, APRIL 20, 2007

Registration opens at 10:00 am. Lunch buffet available from 12:00 Noon.

13.30 – 13.35 Welcome and Opening Words
J. San Miguel, J.-L. Harousseau, M. Aapro

13.35 – 14.40 Opening Talks:

The three musketeers in MM – three presentations on the mechanisms of action and side-effects of new agents

13.35 – 13.50 IMiDs: Lenalidomide and thalidomide. *J.-L. Harousseau (F)*

13.55 – 14.10 Proteasome inhibitor bortezomib for the treatment of multiple myeloma. *P. Sonneveld (NL)*

14.15 – 14.35 Agents in the pipeline for the treatment of multiple myeloma.
M. Engelhardt (GER)

14.40 – 16.10 SESSION I: Biology and Prognostic Indicators

Chair: *H. Avet Loiseau*

14.40 – 15.00 Understanding the biology of multiple myeloma.
P. Liebisch (GER)

15.00 – 15.30 Differentiating MGUS and MM. *J. Blade (SP)*

15.30 – 16.00 New prognostic factors and staging systems in MM.
H. Avet Loiseau (F)

16.10 – 16.45 Break

16.45 – 18.25 SESSION II: Treatment Options

Chair: *M. Boccadoro*

16.45 – 17.10 Treatment options for young patients newly diagnosed with Multiple Myeloma. *J. San Miguel (SP)*

17.20 – 17.45 Treatment options for elderly or frail patients newly diagnosed with Multiple Myeloma. *M. Boccadoro (I)*

17.55 – 18.20 Treatment of relapsed and refractory myeloma.
M. Attal (F)

18.30 Closure of the day

20.00 Buses depart from the hotel lobby to Gala Dinner

SATURDAY, APRIL 21, 2007

09.00 – 10.00 SESSION III: Disease or Treatment Complications

Chair: *A. Palumbo*

09.00 – 09.20 Overcoming thrombosis in MM patients.
A. Palumbo (I)

09.30 – 09.50 Bone integrity and MM patients.
Ø. Hjertner (NO)

10.00 – 10.30 Break

10.30 – 11.15 SESSION IV: Stem Cell Transplantation

Chair: *M. Aapro*

10.30 – 10.45 The role and timing of autologous stem cell transplantation.
J.-L. Harousseau (F)

10.50 – 11.05 The role and timing of allogeneic stem cell transplantation.
J.A. Pérez-Simón (SP)

11.15 – 12.45 SESSION V: Today and Tomorrow

Chairmen: *J. San Miguel, J.-L. Harousseau*

11.15 – 11.35 What should we learn from molecular genetics and gene arrays. *G. Morgan (UK)*

11.45 – 12.05 What is important for patients.
A patient

12.10 – 12.40 Expectations for the future.
Panel discussion led by J. San Miguel and J.-L. Harousseau, addressing ongoing and future studies to improve upon present results

12.45 – 13.00 Learning Assessments.

Attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY afterwards.

13.00 – 14.30 Lunch-buffet and certificate delivery

FACULTY:

Matti S. Aapro
Doyen IMO Clinique de Genolier
Genolier, Switzerland

Michel Attal
Hôpital Purpan
Toulouse, France

Hervé Avet-Loiseau
Centre Hospitalier
Universitaire Hôtel Dieu
Nantes, France

Joan Blade
University of Barcelona
Barcelona, Spain

Mario Boccadoro
University of Torino
Torino, Italy

Monika Engelhardt
Universitäts Klinikum Freiburg
Freiburg, Germany

Jean-Luc Harousseau (Chairman)
University Hospital Nantes
Nantes, France

Øyvind Hjertner
Norwegian University of Science
and Technology (NTNU)
Trondheim, Norway

Peter Liebisch
University Hospital of Ulm
Ulm, Germany

Gareth Morgan
The Royal Marsden Hospital
Sutton, Surrey
UK

Antonio Palumbo
University of Torino
Turino, Italy

José A. Pérez-Simón
Hospital Clinic University
Salamanca, Spain

Jesus F. San-Miguel (Chairman)
Hospital Universitario de
Salamanca and Centro de
Investigacion del Cancer (CIC)
University of Salamanca
Salamanca, Spain

Pieter Sonneveld
Erasmus Medical Center Rotterdam
Rotterdam, The Netherlands



NEW DEVELOPMENTS IN MULTIPLE MYELOMA

Madrid, Spain
Friday, April 20 – Saturday April 21, 2007

Course Objective:

This course will provide the background for haematologists, oncologists and others involved in the treatment of multiple myeloma to understand the basic science and the clinical achievements in multiple myeloma therapy. This is intended to be a practice-oriented course, helping decision-making processes for the clinician. Participants will have an opportunity to discuss patient case studies and interact with experts as well as receive updates on the latest data and advances in this field.


Each participant will receive a certificate of attendance stating that he/she attended the entire course. The certificate of attendance will be distributed only at the end of the meeting, after a learning assessment test.

Target Audience:

Physicians and Other Healthcare Professionals

Official Language:

English – simultaneous translation into Spanish will be available



NEW DEVELOPMENTS IN MULTIPLE MYELOMA

MADRID, SPAIN
FRIDAY, APRIL 20 – SATURDAY APRIL 21, 2007



This course has been approved for CME accreditation by ACOE
(this is mutually recognized by AMA)

This course is supported by educational grants from



NEW DEVELOPMENTS IN MULTIPLE MYELOMA



The field of multiple myeloma has evolved from theory to practical clinical application. The initial successes promise that this area will become very important for cancer patient care. There are many questions that will need evaluation, and the medical community is looking forward to these developments. We wish great success to this meeting, organized in collaboration with a great Faculty and our two centers.

J. San Miguel & J.-L. Harousseau

MADRID, SPAIN
FRIDAY, APRIL 20 – SATURDAY APRIL 21, 2007

CHAIRMEN:

JESUS SAN MIGUEL and JEAN-LUC HAROUSSEAU

SCIENTIFIC COURSE COORDINATOR: MATTI AAPRO

VENUE:

Hotel Meliá Castilla
Capitán Haya 43
28020 Madrid
Spain

*In cooperation with Hospital Clínico Universitario Salamanca,
Salamanca, Spain and CHU Hôtel Dieu, Nantes, France*